DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Onglyza (Saxagliptin Hydrochloride) - Summary

 
 



ONGLYZA SUMMARY

Saxagliptin is an orally-active inhibitor of the DPP4 enzyme.

Monotherapy and Combination Therapy

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. [See Clinical Studies .]

Important Limitations of Use

ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.

ONGLYZA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using ONGLYZA. [See Warnings and Precautions .]


See all Onglyza indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Onglyza (Saxagliptin)

Gliptin Users Don't Seem to Have Higher CV Risk (CME/CE)
Source: MedPage Today Endocrinology [2016.04.25]
(MedPage Today) -- FDA pilot study contradicts earlier results for Onglyza

No increased heart failure risk observed with saxagliptin or sitagliptin
Source: Cardiovascular / Cardiology News From Medical News Today [2016.04.27]
A retrospective cohort study found that patients taking saxagliptin or sitagliptin did not have a higher risk for heart failure compared to those taking other commonly-prescribed medications for...

more news >>

Published Studies Related to Onglyza (Saxagliptin)

Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. [2011.11.12]
BACKGROUND: Few studies have assessed the use of new oral anti-diabetic agents in Asian populations. This study assesses the efficacy and safety of saxagliptin versus placebo in Asian patients with type 2 diabetes mellitus (T2DM)... CONCLUSIONS: Saxagliptin improved glycemic control and was well-tolerated in drug-naive Asian patients with T2DM. Copyright (c) 2002 John Wiley & Sons, Ltd. Copyright (c) 2002 John Wiley & Sons, Ltd.

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. [2011.11]
CONCLUSION: SAVOR-TIMI 53 is testing the hypothesis that treatment with saxagliptin is safe and reduces CV events in high-risk patients with T2DM. Copyright (c) 2011 Mosby, Inc. All rights reserved.

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. [2011.11]
AIM: To assess efficacy and safety of saxagliptin added to metformin versus placebo plus metformin in Asian patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin alone... CONCLUSION: Saxagliptin added to metformin significantly improved glycemic control and was well tolerated in Asian patients with T2DM who had inadequate glycemic control with metformin and diet and lifestyle modification. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.

Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. [2011.09]
AIM: To study the effect of dipeptidyl peptidase-4 (DPP-4) inhibition with saxagliptin on beta-cell function as reflected by the stimulated insulin secretion rate after an enteral glucose load in patients with type 2 diabetes... CONCLUSIONS: DPP-4 inhibition with saxagliptin improves pancreatic beta-cell function in postprandial and fasting states, and decreases postprandial glucagon concentration. Given the magnitude of enhancement of the insulin response in the fasting state, further study into the effect of DPP-4 inhibition on the beta-cell is warranted. (c) 2011 Blackwell Publishing Ltd.

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. [2011.07]
BACKGROUND: The mechanism of action of dipeptidyl peptidase-4 inhibitors, such as saxagliptin, makes them suitable for combination therapy in type 2 diabetes mellitus (T2DM). Genetic, cultural, and environmental differences in individuals from different regions of the world may result in differences in treatment response to oral antidiabetic drugs (OADs). This post-hoc subanalysis assessed the efficacy and safety of saxagliptin as add-on therapy to metformin, glyburide, or a thiazolidinedione in patients with inadequately controlled T2DM in the United States... CONCLUSIONS: This post-hoc analysis in a cohort of US patients with T2DM uncontrolled on monotherapy suggests that saxagliptin 2.5 or 5 mg as add-on therapy to OADs results in improvement across key glycemic parameters compared with placebo add-on and was generally safe and well tolerated.

more studies >>

Reports of Suspected Onglyza (Saxagliptin) Side Effects

Pancreatitis (43)Rash (35)Blood Glucose Increased (32)Drug Ineffective (28)Nausea (25)Diarrhoea (25)Dizziness (22)Pruritus (20)Abdominal Pain Upper (19)Oedema Peripheral (18)more >>


Page last updated: 2016-04-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015